Loading...

NantHealth

DB:NEL
Snowflake Description

High growth potential and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NEL
DB
$111M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

NantHealth, Inc., together with its subsidiaries, operates as an evidence-based personalized healthcare company in the United States and internationally. The last earnings update was 120 days ago. More info.


Add to Portfolio Compare Print
  • NantHealth has significant price volatility in the past 3 months.
NEL Share Price and Events
7 Day Returns
1.5%
DB:NEL
3%
DE Healthcare Services
0.7%
DE Market
1 Year Returns
-65.1%
DB:NEL
16.9%
DE Healthcare Services
-8.7%
DE Market
NEL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NantHealth (NEL) 1.5% 88.1% 65.7% -65.1% - -
DE Healthcare Services 3% 4.4% 25.8% 16.9% 42% 160.8%
DE Market 0.7% 2.2% 8.8% -8.7% 7.6% 9.7%
1 Year Return vs Industry and Market
  • NEL underperformed the Healthcare Services industry which returned 16.9% over the past year.
  • NEL underperformed the Market in Germany which returned -8.7% over the past year.
Price Volatility
NEL
Industry
5yr Volatility vs Market

NEL Value

 Is NantHealth undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of NantHealth to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for NantHealth.

DB:NEL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 12.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:NEL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 1.22
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.222 (1 + (1- 21%) (180.1%))
2.314
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
2
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (2 * 5.96%)
12.15%

Discounted Cash Flow Calculation for DB:NEL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for NantHealth is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:NEL DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 12.15%)
2019 -72.45 Analyst x1 -64.60
2020 -66.18 Analyst x1 -52.62
2021 -34.35 Analyst x1 -24.36
2022 0.05 Analyst x1 0.03
2023 46.83 Analyst x1 26.39
2024 80.09 Est @ 71.05% 40.26
2025 119.98 Est @ 49.8% 53.77
2026 161.88 Est @ 34.93% 64.70
2027 201.58 Est @ 24.52% 71.83
2028 236.31 Est @ 17.23% 75.09
Present value of next 10 years cash flows $190.49
DB:NEL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $236.31 × (1 + 0.23%) ÷ (12.15% – 0.23%)
$1,986.99
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,986.99 ÷ (1 + 12.15%)10
$631.36
DB:NEL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $190.49 + $631.36
$821.86
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $821.86 / 109.49
$7.51
DB:NEL Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:NEL represents 0.96633x of NasdaqGS:NH
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.96633x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 7.51 x 0.96633
€7.25
Value per share (EUR) From above. €7.25
Current discount Discount to share price of €0.98
= -1 x (€0.98 - €7.25) / €7.25
86.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price NantHealth is available for.
Intrinsic value
>50%
Share price is €0.98 vs Future cash flow value of €7.25
Current Discount Checks
For NantHealth to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • NantHealth's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • NantHealth's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NantHealth's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NantHealth's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:NEL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-1.51
NasdaqGS:NH Share Price ** NasdaqGS (2019-03-21) in USD $1.01
Europe Healthcare Services Industry PE Ratio Median Figure of 17 Publicly-Listed Healthcare Services Companies 29.19x
Germany Market PE Ratio Median Figure of 423 Publicly-Listed Companies 18.55x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NantHealth.

DB:NEL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:NH Share Price ÷ EPS (both in USD)

= 1.01 ÷ -1.51

-0.67x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NantHealth is loss making, we can't compare its value to the Europe Healthcare Services industry average.
  • NantHealth is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does NantHealth's expected growth come at a high price?
Raw Data
DB:NEL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.67x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
35.5%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 11 Publicly-Listed Healthcare Services Companies 2x
Germany Market PEG Ratio Median Figure of 275 Publicly-Listed Companies 1.44x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for NantHealth, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on NantHealth's assets?
Raw Data
DB:NEL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $0.47
NasdaqGS:NH Share Price * NasdaqGS (2019-03-21) in USD $1.01
Germany Healthcare Services Industry PB Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 2.77x
Germany Market PB Ratio Median Figure of 571 Publicly-Listed Companies 1.79x
DB:NEL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:NH Share Price ÷ Book Value per Share (both in USD)

= 1.01 ÷ 0.47

2.16x

* Primary Listing of NantHealth.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NantHealth is good value based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess NantHealth's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. NantHealth has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NEL Future Performance

 How is NantHealth expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
35.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is NantHealth expected to grow at an attractive rate?
  • NantHealth's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • NantHealth's earnings growth is expected to exceed the Germany market average.
  • NantHealth's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:NEL Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:NEL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 35.5%
DB:NEL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 26.6%
Europe Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 15.2%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.4%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:NEL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:NEL Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 350 61 13 1
2022-12-31 243 14 -35 1
2021-12-31 178 -21 -66 1
2020-12-31 134 -53 -86 2
2019-12-31 104 -60 -84 2
2018-12-31 90 -127 -162 2
DB:NEL Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 89 -34 -164
2018-06-30 88 -50 -89
2018-03-31 90 -68 -125
2017-12-31 87 -81 -131
2017-09-30 82 -92 -157
2017-06-30 81 -84 -161
2017-03-31 80 -65 -138
2016-12-31 80 -71 -145
2016-09-30 83 -74 -131
2016-06-30 77 -85 -128
2016-03-31 66 -91 -110
2015-12-31 46 -74 -62

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • NantHealth's earnings are expected to grow significantly at over 20% yearly.
  • NantHealth's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:NEL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from NantHealth Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NEL Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.11 0.11 0.11 1.00
2022-12-31 -0.30 -0.30 -0.30 1.00
2021-12-31 -0.57 -0.57 -0.57 1.00
2020-12-31 -0.77 -0.70 -0.83 2.00
2019-12-31 -0.76 -0.59 -0.92 2.00
2018-12-31 -1.48 -1.44 -1.52 2.00
DB:NEL Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -1.51
2018-06-30 -0.81
2018-03-31 -1.10
2017-12-31 -1.13
2017-09-30 -1.31
2017-06-30 -1.32
2017-03-31 -1.18
2016-12-31 -1.30
2016-09-30 -1.24
2016-06-30 -1.29
2016-03-31 -0.20
2015-12-31 -0.69

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if NantHealth will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess NantHealth's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NantHealth has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NEL Past Performance

  How has NantHealth performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NantHealth's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NantHealth does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare NantHealth's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare NantHealth's 1-year growth to the Europe Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
NantHealth's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NantHealth Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NEL Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 88.90 -163.77 76.92 24.69
2018-06-30 88.37 -89.36 77.44 27.60
2018-03-31 89.84 -125.25 78.28 30.09
2017-12-31 86.68 -131.40 74.98 33.86
2017-09-30 82.22 -157.25 70.58 35.84
2017-06-30 81.13 -160.63 75.09 38.05
2017-03-31 80.06 -137.84 95.32 45.54
2016-12-31 80.40 -145.48 105.26 47.31
2016-09-30 82.96 -130.96 105.50 38.98
2016-06-30 76.71 -127.52 101.61 36.04
2016-03-31 66.01 -109.86 80.00 25.14
2015-12-31 46.18 -61.73 55.72 14.25
2015-09-30 47.83 -83.84 66.07 20.82
2015-06-30 43.35 -90.57 61.60 17.93
2015-03-31 38.63 -85.86 53.18 17.32
2014-12-31 33.92 -84.43 46.21 16.98
2013-12-31 26.72 -40.93 35.31 10.75

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if NantHealth has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if NantHealth has efficiently used its assets last year compared to the Europe Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if NantHealth improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess NantHealth's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NantHealth has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NEL Health

 How is NantHealth's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NantHealth's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NantHealth is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • NantHealth's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of NantHealth's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NantHealth Company Filings, last reported 5 months ago.

DB:NEL Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 51.20 199.16 22.84
2018-06-30 148.12 197.89 29.41
2018-03-31 171.04 196.65 46.39
2017-12-31 193.30 195.46 61.66
2017-09-30 208.75 194.30 73.49
2017-06-30 299.82 193.18 92.67
2017-03-31 369.52 192.09 124.89
2016-12-31 411.59 191.04 157.57
2016-09-30 451.14 112.67 75.80
2016-06-30 485.12 112.67 95.31
2016-03-31 202.58 152.67 24.63
2015-12-31 185.01 0.00 7.23
2015-09-30
2015-06-30 235.12 0.00 53.50
2015-03-31 64.80 34.50 225.57
2014-12-31 64.80 34.50 225.57
2013-12-31 20.66 30.57 17.02
  • NantHealth's level of debt (389%) compared to net worth is high (greater than 40%).
  • Unable to establish if NantHealth's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • NantHealth has less than a year of cash runway based on current free cash flow.
  • NantHealth has less than a year of cash runway if free cash flow continues to reduce at historical rates of -10.6% each year.
X
Financial health checks
We assess NantHealth's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NantHealth has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NEL Dividends

 What is NantHealth's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from NantHealth dividends.
If you bought €2,000 of NantHealth shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate NantHealth's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate NantHealth's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:NEL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.5%
Germany Market Average Dividend Yield Market Cap Weighted Average of 331 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:NEL Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as NantHealth has not reported any payouts.
  • Unable to verify if NantHealth's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of NantHealth's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as NantHealth has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess NantHealth's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NantHealth afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NantHealth has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NEL Management

 What is the CEO of NantHealth's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Patrick Soon-Shiong
COMPENSATION $0
AGE 65
TENURE AS CEO 8.7 years
CEO Bio

Dr. Patrick Soon-Shiong, M.D., FRCS (C), FACS, MBBCh, MSS, FRCS (C), is an Owner of Los Angeles Times Communications, LLC. Dr. Soon-Shiong is a physician, surgeon and scientist, invented and developed the revolutionary drug Abraxane. He serves as Chief Executive Officer and as Chairman of NantHealth, Inc. since July 2010 and Director since 2010. Dr. Soon-Shiong served as the Interim Chief Executive Officer of Verity Health System of Califo until January 4, 2018. From 1997- 2010, Dr. Soon-Shiong served as Founder, Chairman and CEO of global pharmaceutical companies American Pharmaceutical Partners and Abraxis BioScience. In 2011, Dr. Soon-Shiong formed NantWorks. He serves as Chief Executive Officer and Chairman of the board of directors of NantWorks. In January 2016, Dr. Soon-Shiong announced the formation of Cancer Moonshot 2020. Dr. Soon-Shiong serves as Chairman and CEO of NantKwest (NK). Dr. Soon-Shiong is Chairman of the Chan Soon-Shiong Family Foundation and Chairman and CEO of the Chan Soon-Shiong Institute of Molecular Medicine. He co-chairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America. Dr. Patrick Soon-Shiong is the Founder of Nant Capital, LLC, NantWorks and NantHealth. He has also spearheaded a cancer moonshot initiative - separate from the effort affiliated with former Vice President Joe Biden - named Cancer Breakthroughs 2020, in 2016 with his firm NantHealth. Dr. Soon-Shiong was a Director of Tronc until April 2017. He is an Adjunct Professor of Surgery at UCLA, and a visiting Professor at the Imperial College of London and Dartmouth College. He is the Executive Director of the UCLA Wireless Health Institute and a board member of the California Telehealth Network. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award. In April 2016, Dr. Soon-Shiong received the Franklin Institute Award for his visionary leadership and commitment to advancing medical and scientific research and bringing new treatment options to cancer patients. Also in April 2016, Dr. Soon-Shiong was honored at the Vatican and received the 2016 Pontifical Key Visionary Award. The award recognized Dr. Soon-Shiong’s contribution to medical innovation and visionary leaders who change the course of history and reduce suffering on a global scale by blending visionary thinking with real action. Dr. Patrick Soon-Shiong holds a degree in medicine from the University of the Witwatersrand and a M.Sc. in science from the University of British Columbia. Dr. Patrick Soon-Shiong is a board certified surgeon and a fellow of the American College of Surgeons and of the Royal College of Physicians and Surgeons of Canada.

CEO Compensation
  • Insufficient data for Patrick to compare compensation growth.
  • Patrick's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the NantHealth management team in years:

1.4
Average Tenure
53
Average Age
  • The average tenure for the NantHealth management team is less than 2 years, this suggests a new team.
Management Team

Patrick Soon-Shiong

TITLE
Founder
AGE
65
TENURE
8.7 yrs

Ron Louks

TITLE
COO & Director
COMPENSATION
$3M
AGE
53
TENURE
1.8 yrs

Bob Petrou

TITLE
Interim Chief Financial Officer
AGE
46
TENURE
0.5 yrs

Brandon Villery

TITLE
VP, General Counsel & Corporate Secretary
TENURE
1.4 yrs

Charles Hunt

TITLE
Vice President of Marketing
TENURE
1.4 yrs

Maureen Becker

TITLE
Vice President of Human Resources
TENURE
1.1 yrs

Bobby Reddy

TITLE
Chief Medical Officer
TENURE
1.8 yrs

Greg Dunko

TITLE
Senior Vice President of Product & Program Management
TENURE
1.4 yrs

Keith Krebs

TITLE
Senior Vice President of Client Services
TENURE
1.4 yrs

Chris House

TITLE
Senior Vice President of Product Development
TENURE
1.4 yrs
Board of Directors Tenure

Average tenure and age of the NantHealth board of directors in years:

2.8
Average Tenure
66
Average Age
  • The average tenure for the NantHealth board of directors is less than 3 years, this suggests a new board.
Board of Directors

Patrick Soon-Shiong

TITLE
Founder
AGE
65
TENURE
8.7 yrs

Ron Louks

TITLE
COO & Director
COMPENSATION
$3M
AGE
53
TENURE
0.8 yrs

Michael Sitrick

TITLE
Director
COMPENSATION
$227K
AGE
71
TENURE
2.8 yrs

Michael Blaszyk

TITLE
Director
COMPENSATION
$232K
AGE
66
TENURE
2.8 yrs

Kirk Calhoun

TITLE
Director
COMPENSATION
$222K
AGE
74
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess NantHealth's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NantHealth has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NEL News

Simply Wall St News

NEL Company Info

Description

NantHealth, Inc., together with its subsidiaries, operates as an evidence-based personalized healthcare company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care. It develops NantHealth solution, an adaptive learning system, including molecular profiling solution, software, and hardware systems infrastructure that collects, indexes, analyzes, and interprets various molecular, clinical, operational, and financial data points derived from various sources to enhance decision-making. The company’s products include GPS Cancer, a molecular profile that integrates whole genome sequencing of tumor and normal germline samples, whole transcriptome sequencing, and quantitative proteomics; GPS Cancer Report, a GPS cancer solution; GPS in rare diseases and chronic illnesses; and Eviti, a decision support solution. It also provides Web-based and mobile software solutions, such as Device Connectivity Suite, a device connectivity and near real-time biometric software and hardware suite; DeviceConX, a device data normalization software; HBox, an Internet of Medical Things and Internet of Things hardware hub; and VitalsConX, a tablet-optimized application. In addition, NantHealth, Inc. offers NaviNet Open, a payer-provider collaboration platform comprising plan central, eligibility and benefit, claims status inquiry, claims management, referral, authorization, document exchange, and AllPayer services; and cloud-based computing, storage, and transport infrastructure-as-a-service solutions. The company was formerly known as Nant Health, LLC and changed its name to NantHealth, Inc. in June 2016. The company was founded in 2010 and is headquartered in Culver City, California. NantHealth, Inc. is as a subsidiary of NantWorks, LLC.

Details
Name: NantHealth, Inc.
NEL
Exchange: DB
Founded: 2010
$97,467,560
109,487,787
Website: http://nanthealth.com
Address: NantHealth, Inc.
9920 Jefferson Boulevard,
Culver City,
California, 90232,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS NH Common Shares Nasdaq Global Select US USD 02. Jun 2016
DB NEL Common Shares Deutsche Boerse AG DE EUR 02. Jun 2016
Number of employees
Current staff
Staff numbers
494
NantHealth employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/21 22:58
End of day share price update: 2019/03/21 00:00
Last estimates confirmation: 2019/01/11
Last earnings filing: 2018/11/21
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.